- Conditions
- Prostate Adenocarcinoma
- Interventions
- Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
- Drug · Radiation
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,050 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 567
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
- Conditions
- Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Interventions
- Apalutamide, Bicalutamide, Biospecimen Collection, Bone Scan, Buserelin, Computed Tomography, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Magnetic Resonance Elastography, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Relugolix, Triptorelin
- Drug · Procedure · Other + 1 more
- Lead sponsor
- NRG Oncology
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 2,753 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2038
- U.S. locations
- 594
- States / cities
- Fairbanks, Alaska • Gilbert, Arizona • Peoria, Arizona + 438 more
- Conditions
- PMM2-CDG, Phosphomannomutase 2 Deficiency
- Interventions
- GLM101 (Part A, Double-blind), GLM101 (Part B, Open-label), Placebo (Part A, Double-blind)
- Drug
- Lead sponsor
- Glycomine, Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 4
- States / cities
- Minneapolis, Minnesota • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Pancreatic Ductal Adenocarcinoma
- Interventions
- ATP150, ATP152, ATP162, Ezabenlimab, VSV-GP154
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Santa Monica, California • Aurora, Colorado + 9 more
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Daratumumab, Dexamethasone, Etentamig, Lenalidomide, Pomalidomide
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 283 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 15
- States / cities
- Little Rock, Arkansas • Miami, Florida • Tampa, Florida + 11 more
- Conditions
- Advanced Solid Neoplasms
- Interventions
- Olaparib
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 24
- States / cities
- Tucson, Arizona • Fullerton, California • Los Angeles, California + 17 more
- Conditions
- Posttraumatic Stress Disorder
- Interventions
- Placebo, Prazosin
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Crohn's Disease
- Interventions
- Placebo for Risankizumab IV, Placebo for Risankizumab SC, Risankizumab IV, Risankizumab On-Body Injector (OBI), Risankizumab SC
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 1,336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 111
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
- Conditions
- Alcohol Use Disorder (AUD), PTSD
- Interventions
- Maltodextrin (Placebo), Psilocybin 25 mg
- Drug
- Lead sponsor
- Nathan Brashares Sackett
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Myeloproliferative Neoplasm, Primary Myelofibrosis
- Interventions
- Placebo, Ropeginterferon alfa-2b
- Other · Biological
- Lead sponsor
- PharmaEssentia
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Kansas City, Kansas + 10 more
- Conditions
- Stress Urinary Incontinence
- Interventions
- Desara® Blue Transobturator Sling, Desara® One Single Incision Sling
- Device
- Lead sponsor
- Caldera Medical, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Hialeah, Florida + 12 more
- Conditions
- Eosinophilic Esophagitis (EoE)
- Interventions
- dupilumab
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 43 more
- Conditions
- Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
- Interventions
- CHS-114, toripalimab
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 12
- States / cities
- Palo Alto, California • Atlanta, Georgia • Louisville, Kentucky + 9 more
- Conditions
- Acute Liver Failure, Acute Liver Injury, Fulminant Hepatic Failure, Hepatic Encephalopathy, Immune Dysregulation
- Interventions
- Diphenhydramine, Equine anti-thymocyte globulin, High-dose methylprednisolone, Methylprednisolone, Placebo for infusions, Placebo for prednisolone, Prednisolone
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 17
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 14 more
- Conditions
- AMR, Antibody-Mediated Rejection, Biopsy-proven Histologic Scores, Kidney Transplantation
- Interventions
- ALXN2030, Placebo
- Drug
- Lead sponsor
- Alexion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 16 more
- Conditions
- Chronic Kidney Diseases, End Stage Kidney Disease (ESRD), Major Depressive Disorder
- Interventions
- Behavioral activation therapy, Bupropion, Clinical Management, Placebo
- Behavioral · Drug · Other
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 4
- States / cities
- Stony Brook, New York • Dallas, Texas • Seattle, Washington
- Conditions
- Crohn's Disease
- Interventions
- Mirikizumab
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 996 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 54
- States / cities
- Dothan, Alabama • Litchfield Park, Arizona • Phoenix, Arizona + 49 more
- Conditions
- Mild Cognitive Impairment
- Interventions
- Placebo oral tablet, extended release metformin
- Drug
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 326 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 22
- States / cities
- Irvine, California • Palo Alto, California • Washington D.C., District of Columbia + 17 more
- Conditions
- Neoplasms
- Interventions
- Cyclophosphamide, Fludarabine, Letetresgene autoleucel (lete-cel, GSK3377794)
- Drug
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 24
- States / cities
- Duarte, California • Stanford, California • Denver, Colorado + 19 more
- Conditions
- Relapsing Multiple Sclerosis (RMS)
- Interventions
- Ofatumumab approved dose, Ofatumumab new dose
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 50 more
- Conditions
- Alcohol Drinking, Alcohol Problem, Posttraumatic Stress Symptom
- Interventions
- Activity scheduling, Coaching calls, Cognitive restructuring, Non-core intervention components
- Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Generalized Myasthenia Gravis, Myasthenia Gravis, Myasthenia Gravis, Generalized, gMG
- Interventions
- Efgartigimod IV, Placebo IV
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Fresno, California • Boca Raton, Florida + 15 more
- Conditions
- Driving Behavior
- Interventions
- Attention Maintenance Training, Hazard Perception Training, Vehicle Maintenance Training
- Behavioral
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 8,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hypothalamic Obesity
- Interventions
- Placebo, Setmelanotide
- Drug
- Lead sponsor
- Rhythm Pharmaceuticals, Inc.
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • San Diego, California • Aurora, Colorado + 11 more